Perspective

Our Perspective

  • An Early Diagnosis of Challenges Ahead for Critical Illness Insurers

    By Adele Groyer |October 02, 2013|English

    Initiatives to sequence 100,000 individual genomes in the UK and to develop a DNA study of one million Americans will create a vast genetic dataset. There is pressure to return incidental, but relevant, findings to participants. Despite this aim being...

    Read More
  • Critical Illness Valuation

    By Steve Rowley |September 12, 2013|English

    Once a Critical Illness product is developed and sold, insurers are required to complete valuation studies regularly to determine if their pricing assumptions are being met and if the product is sufficiently funded to pay all future claims. For this...

    Read More
  • Selling Critical Illness Insurance

    By Steve Rowley |August 19, 2013|English

    The Critical Illness sales process differs from that of many other personal insurance lines. Producers that market Critical Illness insurance see that it affords them an opportunity to provide true value to the consumer. Insurers and advisors realize...

    Read More
  • Critical Illness Compliance Issues

    By Steve Rowley |July 23, 2013|English

    Working through the filing process and addressing various state objections can be a daunting and frustrating task for nearly any insurance product. In the case of Critical Illness (CI) insurance, this task is compounded in many states by their inexperience...

    Read More
  • Critical Illness Claims Adjudication

    By Steve Rowley |June 12, 2013|English

    Critical Illness claim adjudication is an important part of the risk management process. As such, it is important to recognize the unique skills required to properly adjudicate a Critical Illness claim so that the insurer provides fairly the benefits...

    Read More
  • Group Critical Illness Pricing Challenges

    By Steve Rowley |May 06, 2013|English

    In our December 2012 blog on Critical Illness Pricing 101, we discussed some of the steps needed to develop population incidence rates for initial claim cost and the consequent adjustments made, based on underwriting and benefit trigger definitions....

    Read More